Added to YB: 2026-05-14
Pitch date: 2026-05-11
NVO [neutral]
Novo Nordisk A/S
-0.03%
current return
Author Info
Kontra Invest is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 296.60
Price Target
N/A
Dividend
3.91%
EV/EBITDA
8.27
P/E
10.92
EV/Sales
4.43
Sector
Pharmaceuticals
Category
growth
Q1 2026: The Wegovy pill tilts the Novo Nordisk sentiment
NVO (earnings): Q1 beat driven by Wegovy pill launch: DKK 2.3B sales (~$355M, +95% vs consensus), tracking >$2B annualized, already multi-blockbuster status. 80% of users treatment-naïve (minimal cannibalization). Wegovy HD approved at 20.7% weight loss. FY26 guidance raised 1pp to -4%/-12% CER (conservative). WAC cut to $675/mo (2027) offset by cash-pay shift (~30% TRx, 120M addressable TAM). Zenagamtide pipeline elevated. Trading 14.1x 2027E P/E at slight discount to peers despite upside catalysts.
Read full article (10 min)